AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
AN2 Therapeutics shares jump 14.91% premarket after announcing GSK collaboration and Gates Foundation funding for TB drug development.
ByAinvest
Monday, Nov 10, 2025 7:17 am ET1min read
AN2 Therapeutics (NASDAQ: ANTX) surged 14.91% in premarket trading following the announcement of a collaboration with GSK to develop boron-based LeuRS-inhibitors targeting tuberculosis (TB), supported by a third year of funding from the Gates Foundation. The partnership leverages AN2’s proprietary boron chemistry platform, which the company claims enables novel drug discovery for infectious diseases and oncology targets. CEO Eric Easom emphasized the potential of this approach to address unmet medical needs in TB, NTM lung disease, and solid-tumor oncology. The collaboration with GSK, a global biopharma leader, and continued Gates Foundation backing underscore the strategic and financial validation of AN2’s technology, likely driving investor optimism. The news aligns with the stock’s upward movement, reflecting confidence in the company’s pipeline and partnership potential.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet